Factors that control extravascular fibrinolysis

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 6, 1996, Pages 479-488

  Chung, Soo Il ^a   Lee, Soo Young ^b   Uchino, Ryogin ^c   Carmassi, Franco ^d  

^a Mogam Biotechnology Research Institute   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c KUMAMOTO ROSAI HOSPITAL   (Japan)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

extravascular fibrinolysis; factor XIII; fibrinolysis; fibrinolytic inhibitors; plasminogen

Indexed keywords

BLOOD CLOTTING FACTOR 13; PLASMINOGEN;

EXTRAVASCULAR SPACE; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030453409     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999048     Document Type: Review

References (128)

1. Clark RAF: Overview and general considerations of wound repair. In: Clark RAF, PM Henson (Eds): The Molecular and Cellular Biology of Wound Repair. Plenum Press, New York, 1988, pp 3-23.
2. Dvorak HF, AP Kaplan, RAF Clark: Potential function of the clotting system in wound repair. In: Clark RAF, PM Henson (Eds): The Molecular and Cellular Biology of Wound Repair. Plenum Press, New York, 1988, pp 57-77.
3. Wahl LM, SM Wahl: Inflammation. In: Cohen IK, RF Dieglemann, WJ Lindblad (Eds): Wound Healing: Biochemical and Clinical Aspects. Saunders, Philadelphia, 1992, pp 40-62.
4. Mast BA: The skin. In: Cohen IK, RF Dieglemann, WJ Lindblad (Eds): Wound Healing: Biochemical and Clinical Aspects. Saunders, Philadelphia, 1992, pp 344-355.
5. Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659, 1986.
6. Firestein GS, NJ Zvaifler: Rheumatoid arthritis: A disease of disordered immunity. In: Gallin JI, IM Goldstein, R Snyderman (Eds): Inflammation: Basic Principles and Clinical Correlates, 2nd ed., Raven Press, New York, 1992, pp 959-976.
7. Carmassi F, F De Negri, M Morale, R Puccetti, SI Chung: Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis. Int J Tissue React 16:89-93, 1994.
8. Zivelin A, LV Rao, SI Rapaport: Evidence for an essential of tissue factor dependent blood coagulation in the pathogenesis of the local Shwartzman reaction. Blood Cells Mol Dis 21:9-19, 1995.
9. Dejana E, M Corada, MG Lampugnani: Endothelial cell to cell junctions. FASEB J 9:910-918, 1995.
10. Baggiolini M, B Dewald, A Walz: Interleukin 8 and related chemotactic cytokines. In: Gallin JI, IM Goldstein, R Snyderman (Eds): Inflammation: Basic Principles and Clinical Correlates, 2nd ed., Raven Press, New York, 1992, pp 9247-9264.
11. Caveda L, M Corada, I Martin-Padura, A Del Maschio, F Breviario, MG Lampugnani, E Dejana: Structural characteristics and functional role of endothelial cell to cell junctions. Endothelium 2:1-10, 1994.
12. Hoek JB: Intracellular signal transduction and the control of endothelial permeability. Lab Invest 67 1-3, 1992.
13. Esposito C, H Gerlach, J Bret, D Stern, H Vlassara: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased permeability and modulation of cell surface coagulant properties. J Exp Med 170:1387-1407, 1989.
14. Conforti G, C Dominguez-Jimenez, A Zanetti, MA Gimbrone, O Cremona, PC Machisio, F Dejana: Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 80:437-446, 1992.
15. Senger D, L Van De Water, L Brown, J Nagy, K-T Yeo, T-K Yeo, B Berse, R Jackman, A Dvorak, H Dvorak: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993.
16. Dvorak H, NS Orenstein, AC Carvalho, WH Churchill, AM Dvorak, SJ Galli, J Feder, AM Bitzner, J Rypyse, P Giovinco: Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122:166-174, 1979.
17. Senger DR, SJ Galli, AM Dvorak, CA Perruzzi, VS Harvey, HF Dvorak: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1986.
18. Collins PD, DT Connolly, TJ Williams: Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 109:195-199, 1993.
19. Dvorak HF, LF Brown, M Detmar, AM Dvorak: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995.
20. Nagy JA, EM Masse, KT Herzberg, MS Meyers, K-T Yeo, T-K Yeo, TM Sioussat, HF Dvorak: Pathogenesis of ascites tumor growth, vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res 55:360-368, 1995.
21. Ferrara N, KA Houck, L Jakeman, DW Leung: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32, 1992.
22. Houck KA, DW Leung, AM Rowland, J Winer, N Ferrara: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037, 1992.
23. Tischer E, R Mitchell, T Hartman, M Silva, D Gospodarowicz, JC Fiddes, JA Abraham: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991.
24. Park L, G-A Keller, N Ferrara: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extravascular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326, 1993.
25. Plate KH, G Breier, HA Welch, W Risau: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-848, 1992.
26. Berkman RA, MJ Merrill, WC Reinhold, WT Monacci, A Saxena, WC Clark, JT Robertson, IU Ali, EH Oldfield: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153-159, 1993.
27. Goldman CK, J Kim, WL Wong, V King, T Brock, GY Gillespie: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133, 1993.
28. Pepper MS, N Ferrara, L Orci, R Montesanto: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831 1992.
29. Jakeman LB, J Winer, GL Bennett, CA Altar, N Ferrara: Binding sites for vascular endothelial growth factor are localised on endothelial cells in adult rat tissues. J Clin Invest 89:244-253, 1992.
30. Dvorak HF, TM Sioussal, LF Brown, B Berse, JA Nagy, A Sotrel, FJ Manseau, L Van De Water, DR Senger: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278, 1991.
31. Gitay-Goren H, S Soker, I Vlodavsky, G Neufled: The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267:6093-6102, 1992.
32. Millauer B, S Wizigmann Voos, H Schnurch, R Martinez, N Moller, W Risau, A Ullrich: High affinity VEGF binding and developmental expression suggests flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846, 1993.
33. De Vries C, JA Escobedo, H Ueno, K Houck, N Ferrara, LT Williams: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992.
34. Terman BI, M Dougher-Vermazen, ME Carrion, D Dimitrov, DC Aemellino, D Gospodarowicz, P Bohlen: Identification of the KDR tyrosine kinase us a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586, 1992.
35. Galland F, A Karamysheva, MJ Pebusque, JP Borg, R Rottapel, P Dubreuil, U Rosnet, D Birnbaum: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8:1233-1240, 1993.
36. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138:213-221, 1991.
37. 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 268:7685-7692, 1991.
38. Kohn S, JA Nagy, HF Dvorak, AM Dvorak: Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 67:596-607, 1992.
39. Qu-Hong I, JA Nagy, DR Senger, HF Dvorak, AM Dvorak: Ultrastructure localisation of vascular permeability factor/vascular endothelial growth factor to the abluminal plasma membrane and vesicular-vacuolar organclles of tumor microvascular endothelium. J Histochem Cytochem 43:381-389, 1995.
40. Dvorak AM, S Kohn, ES Morgan, P Fox, JA Nagy, HF Dvorak: The vesiculo-vacuolar organelle (VVO) - A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukocyte Biol 59:100-115, 1996.
41. Rippe B, B Haraldsson: Transport of macromolecules across microvascular walls: The two-pore theory. Physiol Rev 74:163-219, 1994.
42. Senger DR, HF Dvorak: Vascular permeability factor: A protein mediator that induces tumor vessel hyperpermeability and promotes endothelial cell growth. In: Black PM, L Lampson (Eds): Human Astrocytomas. Blackwell Scientific Publications, Edinburgh, 1993, pp 250-260.
43. Ferrara N, K Houck, L Jakeman, J Winer, D Leung: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47:211-218, 1991.
44. Mandriota SJ, G Seghezzi, JD Vassalli, N Ferrara, S Wasi, R Mazzieri, P Mignatti, MS Pepper: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270:9709-9716, 1995.
45. Pepper MS, N Ferrara, L Orci, R Montesano: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906, 1991.
46. Clauss M, M Gerlach, H Gerlach, J Brett, F Wang, PC Familletti, Y-CE Pan, JV Olander, DT Connolly, D Stern: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1991.
47. Connolly DT, DM Heuvelman, R Nelson, JV Olander, BL Eppley, JJ Delfino, NR Siegel, RM Leimgruber, J Feder: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989.
48. Leung DW, G Cachianes, W-J Kuang, DV Goeddel, N Ferrara: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989.
49. 165 and PDGF-BB. Anat Embryol 186:251-257, 1992.
50. Brown LF, K-T Yeo, B Berse, T-K Yeo, DR Sender, HF Dvorak, L Van De Water: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-1379, 1992.
51. Kock A, L Harlow, G Naines, E Amento, E Umemori, W Wong, R Pope, N Ferrara: Vascular endothelial cell growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149-4156, 1994.
52. Delmer M, L Brown, K Claffey, K-T Yeo, O Kocher, R Jackman, B Berse, HF Dvorak: Overexpression of vascular permeability factor and its receptors in psoriasis. J Exp Med 180:1141-1146, 1994.
53. Bull RH, DO Bates, PS Mortimer: Intravital video-capillaroscopy for the study of the microcirculation in psoriasis. Br J Dermatol 126:436-445, 1992.
54. Brown LF, SM Olbricht, B Berse, RW Jackman, G Matsueda, KA Tognazzi, EJ Manseau, HF Dvorak, L Van De Water: Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial receptors in delayed hypersensitivity skin reactions. J Immunol 154:2801-2807, 1995.
55. Cullian BK, RD Koos: Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829-837, 1993.
56. Kamat BR, LF Brown, EJ Manseau, DR Senger, HF Dvorak: Expression of vascular permeability factor/vascular endothelial growth factor by human granulocytes and theca lutein cells: Role in corpus luteum development. Am J Pathol 146:157-165, 1995.
57. Lewis MS, F Carmassi, SI Chung: Cooperative association of plasminogen with fibrinogen. Biochemistry 11:3874-3879, 1984.
58. Sakata Y, K Tateno, T Tamaki, N Aoki: Calcium-dependent binding of alpha-2-plasmin inhibitor to fibrin. Thromb Res 16:279-282, 1979.
59. Mosher D: Crosslinking of cold insoluble globulin by fibrin stabilizing factor. J Biol Chem 250:6614-6621, 1975.
60. Skorstengaad K, T Halkier, P Hojrup, DF Mosher: Sequence location of putative transglutaminase crosslinking site in human vitronectin. FEBS Lett 26:269-274, 1990.
61. Bale MD, DF Mosher: Thrombospondin is a substrate for blood coagulation F-XIIIa. Biochemistry 25:5667-5673, 1986.
62. Hada M, M Kaminski, P Bockenstedt, J McDonagh: Covalent crosslinking of von Willebrand factor to fibrin. Blood 68:95-101, 1986.
63. Varadi A, L Patthy: Location of plasminogen-binding sites in human fibrin(ogen). Biochemistry 23:2108-2112, 1983.
64. Chung SI, MS Lewis: Association of Factor XIII with fibrinogen. Fed Proc 45:924 (Abst), 1986.
65. Chung SI, JE Folk, JS Finlayson: Enhanced affinity of fibrinogen and factor XIII induced by limited proteolysis. Thromb Hemostas 42:276 (Abst), 1979.
66. Gurewich V, R Pannell: Fibrin-binding and zymogenic properties of singlechain urokinase (pro-urokinase). Semin Thromb Hemostas 13:146-151, 1987.
67. Gurewich V: Activation of fibrin-specific plasminogen by pro-urokinase and its complementaries with that by tissue plasminogen activator. Enzyme 40:97-108, 1988.
68. Collen D: Fibrin-specific thrombolytic agents. Schweiz Med Wochenschr 117:1791-1798, 1987.
69. Ichinose A, J Minuro, T Koide, N Aoki: Histidine-rich glycoprotein and alpha 2-plasmin inhibitor of plasminogen binding to fibrin. Thromb Res 33:401-407, 1984.
70. Lijnen HR, B Van Hoef, D Collen: On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha-2-antiplasmin and fibrin. Eur J Biochem 120:149-154, 1981.
71. Greenberg CS, MS Shuman: The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem 257:6096-6101, 1982.
72. Yeo T-K, HF Dvorak: Tumor stroma: In: Colvin RB, AK Bhan, RT McClusky (Eds): Diagnostic Immunopathology, 2nd ed. Raven Press, New York, 1995, pp 685-697.
73. Dano K, PA Andreasen, J Grondahl-Hansen, P Kristensen, LS Nielsen, L Skriver: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985.
74. Dvorak HF, DR Senger, AM Dvorak, VS Harvey, J McDonagh: Regulation of extravascular coagulation by microvascular permeability. Science 227:1059-1061, 1985.
75. Nagy JA, LF Brown, DR Senger, N Lanir, L Van de Water, AM Dvorak, HF Dvorak: Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 948:305-326, 1989.
76. Chang P, DL Aronson, DG Borenstein, CM Kessler: Coagulant proteins and thrombin generation in synovial fluid: A model for extravascular coagulation. Am J Hematol 50:79-83, 1995.
77. Dvorak HF, SC Quay, NS Orenstein, AM Dvorak, P Hahn, AM Bitzer, AC Carvalho: Tumor shedding and coagulation. Science 212:923-924, 1981.
78. Rickles FR, GA Hair, RA Zeff, E Lee, RD Bona: Tissue factor expression in human leukocytes and tumor cells. Thromb Haemostas 74:391-395, 1995.
79. Carmassi F, FD Negri, M Morale, R Puccetti, KY Song, SI Chung: Assessment of coagulation and fibrinolysis in synovial fluid of rheumatoid arthritis patients. Fibrinolysis 8:162-171, 1994.
80. Olman MA, N Mackman, CL Gladson, KM Moser, DJ Luskutoff: Changes in procoagulant and fibrinolytic gene expression during bleomycine-induced lung injury in the mouse. J Clin Invest 96:1621-1630, 1995.
81. Drake TA, JH Morrissey, TS Edgington: Selective cellular expression of tissue factor in human tissue. Implication of disorders of hemostasis and thrombosis. Am J Pathol 134:1087-1097, 1989.
82. Weiss HJ, VT Turitto, HR Baumgartner, Y Nemerson, T Hoffman: Evidence for the presence of tissue factor activity on subendothelium. Blood 73:968-975, 1989.
83. Brox JH, B Østerud, E Bjorklid, JW Fenton II: Production and availability of thromboplastin endothelial cells: The effects of thrombin, endotoxin and platelets. Br J Haematol 57:239-245, 1984.
84. Schorer AE, PD Rick, WR Swaim, CF Moldow: Structural features of endotoxin required for stimulation of endothelial cell tissue factor production: Exposure of preformed tissue factor after oxidant-mediated endothelial injury. J Lab Clin Med 106: 38-46, 1985.
85. Archipoff G, A Beretz, J-M Freyssinet, C Lein-Soyer, C Brisson, JP Cazanave: Heterogeneous regulation of constitutive thrombomodulin or inducible tissue factor activities on the surface of human saphenous vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem J 273:679-684, 1991.
86. Carlsen E, MB Stinessen, H Prydz: Differential effect of alpha-interferon and gamma-interferon on thromboplastin response in monocytes and endothelial cells. Clin Exp Immunol 70:471-478, 1987.
87. Grabowski EF, DB Zuckerman, Y Nermerson: The functional expression of tissue factor by fibroblasts and endothelial cells under low flow conditions. Blood 81:3265-3270, 1993.
88. LybergT, KS Galdal, SA Evensen, H Prydz: Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol 53:85-95, 1983.
89. Bevilacqua MP, JS Pober, GR Majeau, W Fiers, RS Cotran, MA Gimbrone Jr: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83:4533-4537, 1986.
90. Weis JR, RE Pitas, BD Wilson, GM Rogers: Oxidized low-density lipoprotein increased cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J 5:2459-2465, 1991.
91. Ogawa S, H Gertach, C Esposito, et al: Hypoxia modulates the barrier and coagulation function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest 85: 1090, 1990.
92. Ishii H, S Horie, K Kizaki, M Kazama: Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 80:2556-2562, 1992.
93. Ryan J, J Brett, P Tijburg, RR Bach, W Kiesiel, D Stern: Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80:966-974, 1992.
94. Østerud B: Cellular interactions in tissue factor expression by blood monocytes. Blood Coag Fibrinolysis Suppl 1:S20-25, 1995.
95. McKee PA, P Mattack, RL Hill: Subunit structure of human fibrinogen, soluble fibrin, and crosslinked insoluble fibrin. Proc Natl Acad Sci USA 66:738-745, 1970.
96. Kanaide H, JR Shainoff: Crosslinking of fibrinogen and fibrin by fibrin stabilizing factor. J Lab Clin Med 85:574-597, 1975.
97. Pisano LL, JS Finlayson, MP Peyton: Cross-link in fibrin polymerized by factor XIII: ε(γ-glutamyl)lysine. Science 160:892-893, 1968.
98. Mosesson MW, KR Siebenlist, DL Amrani, JP DiOrio: Identification of covalently linked trimeric and tetrameric D domains in crosslinked domains in crosslinked fibrin. Proc Natl Acad Sci USA 86:1113-1117, 1989.
99. Shainoff JR, DA Urbanic, PM DeBello: Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. Identification of a rapid mode of hybrid alpha-/gamma-chain cross-linking that is promoted by the gamma-chain cross-linking. J Biol Chem 266: 6429-6437, 1991.
100. Shainoff JR, R Valenzuela, DA Urbanic, PM DiBello, FV Lucas, R Graor: Fibrinogen Aα and γ-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease. Blood Coag Fibrinolysis 1:499-503, 1990.
101. 2-plasmin inhibitor to fibrin by fibrin stabilizing factor. J Clin Invest 65:290-297, 1983.
102. Folk JE, JS Finlayson: The ε(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv Prot Chem 31:1-33, 1977.
103. Chung SI, JE Folk: Kinetic studies with transglutaminases of human blood enzymes (factor XIII) and guinea pig hair follicle enzyme. J Biol Chem 247:2798-2807, 1971.
104. Chung SI: Comparative studies of tissue transglutaminases and factor XIII. Ann NY Acad Sci 202:240-255, 1972.
105. Folk JE, SI Chung: Structure and mechanism of action of transglutaminase. Adv Enzymol 38:109-191, 1973.
106. Chung SI, MS Lewis, JE Folk: Relationship of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem 249:940-950, 1973.
107. Chung SI: Multiple molecular forms of transglutaminases in human and guinea pig. In: Market CL (Ed): Isozymes, VoI I. Academic Press, New York, 1975, pp 259-274.
108. Folk JE, SI Chung: Blood coagulation factor XIII: Relationship of some biological properties of subunit structure. Cold Spring Harbor Conference on Cell Proliferation, Proteases and Biological Control 2:157-170, 1975.
109. Board PG, MS Losowsky, KJA Miloszewski: Factor XIII: Inherited and acquired deficiency. Blood Rev 7:229-242, 1993.
110. Carmassi F, SI Chung: Regulation of fibrinolysis by factor XIII. In: Davidson JF, F Bachmann, C Bouvier, EKO Kruithof (Eds): Progress in Fibrinolysis. Churchill Livingstone, Edinburgh, 1983, pp 281-285.
111. Francis CW, VJ Marder: Increased resistance to plasmic degradation of fibrin with highly crosslinked α-polymer chains formed at high factor XIII concentrations. Blood 71:1361-1365, 1988.
112. Chung SI, D Galanakis, JE Folk: Factors that influence factor XIIIa catalytic activity in vivo. In: McDonagh J, R Seitz, R Egbring (Eds): Factor XIII. Schattauer, Stuttgart, 1993, pp 31-39.
113. Furguson EW, GE Sander: Fibrin ε(γ-glutamyl)lysine crosslink acceleration by red blood cells. Nature 278:183-185, 1979.
114. Gulanakis DK, BP Lane, SR Simon: Albumin modulates lateral assembly of fibrin polymers: Evidence of enhanced fine fibrin formation and of unique synergism with fibrinogen. Biochemistry 26:2389-2340, 1987.
115. Uchino R, M Cardinali, SI Chung: Regulation of extravascular fibrinolysis by factor XIII. Fibrinolysis 5:93-98, 1991.
116. Galanakis DK, P Laurent, A Janoff, SI Chung: Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma. Science 217:642-645, 1982.
117. Roth WJ, SI Chung, A Janoff: Inactivation of alveolar macro phage transglutaminase by oxidant in cigarette smoke. J Leukocyte Biol 39:630-644, 1986.
118. Roth WJ, H Fleit, SI Chung, A Janoff: Characterization of two distinct transglutaminases of murine bone marrow-derived macrophages: Effects of exposure of viable cells to cigarette smoke on enzyme activity. J Leukocyte Biol 42:9-20, 1987.
119. Uchino R, M Cardinali, SI Chung, Y Miyauchi: Influence of albumin on tissue fibrinolysis. Thromb Haemostas 62:248 (Abst), 1989.
120. Carmassi F, F De Negri, M Morale, R Puccetti, KY Song, SI Chung: Assessment of coagulation and fibrinolysis in synovial fluid of rheumatoid arthritis patients. Fibrinolysis 8:162-171, 1994.
121. Takashima S, M Koga, K Tanaka: Fibrinolytic activity of human brain and cerebrospinal fluid. Br J Exp Pathol 50:533-539, 1969.
122. Whitelaw A, L Creighton, P Gaffney: Fibrinolytic activity in cerebrospinal fluid after intraventricular hemorrhage. Arch Dis Child 66:808-809, 1991.
123. Ramo OJ, R Sawaya, M Zuccarello: Fibrinolytic enzymes in the normal central nervous system. In: Sawaya R (Ed): Fibrinolysis and the Central Nervous System. Hanley & Belfus, Philadelphia, 1990, pp 26-32.
124. Rao JS, M Chen, BW Festoff: Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid. J Neurosci Res 34:340-345, 1993.
125. Festoff BW, JS Rao, M Chen: Protease nexin 1, a thrombin and urokinase-inhibiting serpin, is concentrated in normal human cerebrospinal fluid. Neurology 42:1361-1366, 1992.
126. 1-antichymotrypsin, in normal human cerebrospinal fluid. J Neurochem 58:88-94, 1992.
127. Whitelaw A, MC Mowinckel, U Abildgaard: Low levels of plasminogen in cerebrospinal fluid after intraventricular hemorrhage: A limiting factor for clot lysis. Acta Paediat 84:933-936, 1995.
128. Lee SY, SK Chang, SI Chung: Prevention of Shwartzman reaction in factor XIII deficiency. Thromb Haemostas 46:763 (Abst), 1981.